Aquestive Therapeutics Inc (AQST)vsMerck & Company Inc (MRK)
AQST
Aquestive Therapeutics Inc
$4.25
0.00%
HEALTHCARE · Cap: $469.25M
MRK
Merck & Company Inc
$135.84
+0.21%
HEALTHCARE · Cap: $316.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 130727% more annual revenue ($65.77B vs $50.27M). MRK leads profitability with a 13.6% profit margin vs -137.1%. MRK earns a higher WallStSmart Score of 50/100 (D+).
AQST
Avoid28
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.2%
Fair Value
$2.56
Current Price
$4.25
$1.69 premium
Margin of Safety
-60.9%
Fair Value
$81.38
Current Price
$135.84
$54.46 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 65.7% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Weak financial health signals
Premium valuation, high expectations priced in
4.9% revenue growth
ROE of 7.6% — below average capital efficiency
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : AQST
The strongest argument for AQST centers on Revenue Growth, Debt/Equity. Revenue growth of 65.7% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : AQST
The primary concerns for AQST are EPS Growth, Market Cap, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Return on Equity.
Key Dynamics to Monitor
AQST profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
AQST carries more volatility with a beta of 1.43 — expect wider price swings.
AQST is growing revenue faster at 65.7% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 28/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aquestive Therapeutics Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and marketing various products to address unmet medical needs in the United States and internationally. The company is headquartered in Warren, New Jersey.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?